Pfizer  logo

Pfizer PFE

$ 24.92 -0.74%

Quarterly report 2024-Q3
added 11-04-2024

report update icon

Country

usaUSA

IPO year

-

Industry

Biotechnology

Stock Exchange

NYSESPB

CEO

Dr. Albert Bourla

Employees in the company

88 300

Shares

5.64 B

Market Cap[1]

$ 141 B

EBITDA (LTM)

$ 5.52 B

P/E (LTM)

29.9

P/S (LTM)

2.64

EPS (LTM)

0.93

Pfizer is a global pharmaceutical company that has been in operation for over 170 years. The company is headquartered in New York City and has a presence in over 150 countries worldwide. Pfizer's mission is to discover, develop, and deliver innovative medicines and vaccines that improve the lives of people around the world.

Pfizer has a diverse portfolio of products that address a range of health conditions, including cardiovascular disease, oncology, inflammation, immunology, and rare diseases. Some of the company's most well-known products include Lipitor, Viagra, and Lyrica.

In addition to developing new treatments, Pfizer is committed to improving access to healthcare for people in need. The company has established partnerships with governments, non-governmental organizations, and healthcare providers to expand access to its medicines and vaccines.

Pfizer is also dedicated to sustainability and reducing its environmental impact. The company has set ambitious goals to reduce greenhouse gas emissions, water consumption, and waste generation across its operations.

As a leading pharmaceutical company, Pfizer is constantly innovating and adapting to meet the changing needs of patients and healthcare providers. With a focus on research and development, access to healthcare, and sustainability, Pfizer is poised to continue making a positive impact on global health for years to come.

Other stocks of industry "Biotechnology"

Issuer Price % 24h Market Cap Exchange Country
Sorrento Therapeutics Sorrento Therapeutics
SRNE
$ 0.27 -29.58 % $ 126 M Nasdaq Global Select Market usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.11 35.12 % $ 105 M Nasdaq Global Market usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 10.41 -5.36 % $ 43.9 M Nasdaq Global Market usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 1.48 -7.22 % $ 8.2 M Nasdaq Capital Market usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
$ 1.47 -5.16 % $ 5.39 M Nasdaq Capital Market usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
$ 4.93 1.02 % $ 90.8 M Nasdaq Global Select Market britainBritain
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 2.4 -5.8 % $ 105 M Nasdaq Global Select Market,SPB usaUSA
Advaxis Advaxis
ADXS
$ 0.31 -9.65 % $ 45.9 M Nasdaq Capital Market usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
$ 3.93 -5.76 % $ 99.8 M Nasdaq Capital Market usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
$ 6.2 - $ 154 M Nasdaq Capital Market usaUSA
Zymeworks Zymeworks
ZYME
$ 6.42 - $ 404 M NYSE canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
$ 10.5 - $ 231 M Nasdaq Global Market usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
$ 12.18 1.42 % $ 1.57 B Nasdaq Capital Market usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
$ 9.5 - $ 1.7 B Nasdaq Global Select Market usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
$ 2.58 -4.8 % $ 255 M Nasdaq Global Select Market usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
$ 0.56 7.23 % $ 2.72 M Nasdaq Global Select Market usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
$ 0.5 - $ 7.46 M Nasdaq Global Market israelIsrael
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
$ 179.68 - $ 10.9 B Nasdaq Global Market,SPB usaUSA
Albireo Pharma Albireo Pharma
ALBO
$ 44.15 -0.23 % $ 916 M Nasdaq Capital Market usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
$ 0.32 - $ 23.9 M Nasdaq Global Select Market usaUSA

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.